BACKGROUND: Stereotactic body radiotherapy (SBRT) is an alternative to surgery for clinical stage I non-small cell lung cancer (NSCLC), but comparing its effectiveness is difficult because of differences in patient selection and staging. METHODS: Two databases were combined which contained patients treated from 1999 to 2008 by lobectomy (LR, n 5 132), sublobar resection (SLR, n 5 48), and SBRT (n 5 137) after negative staging. Univariate and multivariate analysis were performed for survival (OS), total recurrence control (TRC comprises local-regional and distant control), and locoregional control (LRC) in our entire population. A matchedpair analysis was also performed that compared surgery and SBRT results. Median follow-up for the entire study population was 25.8 months. RESULTS: On univariate analysis, OS was significantly worse with SBRT and also correlated with histology, the Charlson comorbidity index, tumor size, and aspirin use; TRC correlated only with histology; and no variable significantly correlated with LRC. OS was significantly poorer for SBRT in the matched-pair analysis than for patients treated with surgery, but TRC and LRC were not significantly different between these groups. Multivariate analyses including propensity score as a covariate (controlling for all factors affecting treatment selection) found that OS correlated only with Charlson comorbidity index, and TRC correlated only with tumor grade. LRC correlated only with tumor size with or without propensity score correction. CONCLUSIONS: This retrospective study has demonstrated similar OS, LRC, and TRC with SBRT or surgery after controlling for prognostic and patient selection factors. Randomized clinical trials are needed to better compare the effectiveness of these treatments. Cancer 2013;119:2683-91.
INTRODUCTION
Since 1962, lobectomy (LR) has been considered to be an acceptable alternative to pneumonectomy for patients with clinical stage I non-small cell lung cancer (NSCLC) when tumors can be removed with negative resection margins. 1 A prospective, randomized trial demonstrated the inferiority of sublobar resection (SLR) to LR with regards to local control and survival, with no difference between the 2 in the risk of surgical complications or postoperative lung function. 2 Therefore, SLR is generally recommended only for select populations or patients unable to tolerate a LR. 3 Stereotactic body radiotherapy (SBRT), also referred to as stereotactic ablative body radiation (SABR), delivers very high radiation doses to restricted volumes over 1 to 5 treatment days using multiple precisely aimed radiotherapy beams. This approach has emerged as an alternative to surgery for medically inoperable patients with early-stage cancers. Studies at individual centers 4, 5 and a multi-institutional investigation conducted by the Radiation Therapy and Oncology Group (RTOG) 6 have demonstrated excellent rates of locoregional control (LRC), disease-free survival, and overall survival (OS). This success has raised the issue of whether SBRT/SABR might be equally effective as surgery for medically fit patients. However, there are clearly substantial differences between patients treated with surgery or SBRT/SABR in retrospective series with regard to age, performance status, comorbid medical conditions, and so forth, that make direct comparisons of results problematic.
We therefore sought to compare results of SBRT/ SABR to surgery for patients with stage I NSCLC by identifying prognostic factors and then using these factors in performing a matched-pair analysis to try to correct for at least some of the biases in treatment assignment between these modalities. Our results suggest that the 2 approaches provide similar OS, LRC, and TRC, which supports performing a phase III trial comparing these two treatment techniques.
MATERIALS AND METHODS
We combined de-identified databases of lung cancer patients from 4 institutions where 639 patients underwent surgical resection from 1999 to 2008 7, 8 and 1 institution where 137 patients underwent SBRT/SABR 9 from 2000 to 2008. One hundred eighty patients were in the surgical group. 180 resections (132 treated with LR and 48 with SLR, all wedge resections) had negative preoperative staging with PET-CT (no ct/pet performed in 87), negative lymph nodes at surgery (node positive 117), T1-T2 tumors (161 T3-T4) and pathologically-confirmed squamous cell, adenocarcinoma, or non-small cell "not otherwise specified" (NOS) histology (other histologies 5 79) who did not received adjuvant or neoadjuvant chemotherapy (chemotherapy received by 181) or radiotherapy. All SBRT/SABR patients included in our analysis received a minimum prescription tumor dose of 100 Gy 10 10 and had biopsy-proven NSCLC, but did not undergo lymphadenectomy or lymph node staging. The mean dose was 60 Gy in 3 fractions. Range of doses was 48 to 60 Gy in 3 to 5 fractions. Three-dimensional treatment planning was used to stereotactically direct a total of 10 to 12 non-coplanar, nonopposed beams to deliver the dose to the PTV. Pencil beam algorithm and no heterogeneity corrections were used in the first 102 patients. The last 35 patients were treated with a collapsed-cone algorithm and heterogeneity corrections. Table 1 compares the characteristics of the SBRT/ SABR and 3 surgical groups. The SBRT/SABR patients were older and had significantly higher mean values (assessed by the unpaired t test) for tumor diameter (P 5 .012), age (P < .001), and Charlson comorbidity index 11 (P < .001) than the surgery patients. The proportion of tumors described as NSCLC-NOS was higher in the SBRT/SABR patients (43%, or 59 of 137) compared to the surgery patients (8%, or 14 of 180).
Statistical Analysis
We evaluated factors potentially affecting OS, TRC, and LRC in the combined set of 137 SBRT/SABR patients and 180 surgery patients. Local and locoregional control were defined as the absence of any recurrence in the ipsilateral lung, and the ipsilateral lung, bronchial stump/suture line, and N1-N3 nodal areas respectively. Total recurrence control was defined by the absence of any recurrence (local, regional, or disseminated). Follow-up times used for OS, LRC, and TRC were from the date of surgery or last day of SBRT. Ipsilateral pulmonary recurrences were only included as a local recurrence if the involved physicians were certain that this tumor was recurrent. In equivocal cases, we considered the tumor to be a second primary cancer and censored the patient from our study group. 7, 8 Overall survival was defined as being alive with or without disease. The Kaplan-Meier method was used to calculate survival/control rates. Univariate comparisons of these estimates were performed using the log-rank test. A P value of 0.05 was chosen to represent statistical significance. Matchpairs were constructed for evaluation of TRC, LRC, and disseminated control by matching by pathology, age, size and sex, but not Charlson comorbidity index or aspirin use, which were used only for the OS matched-pair analysis. All matching was performed in a 1:1 ratio. Age and tumor size were not dichotomized in the matching, but were evaluated as continuous variables. Multivariate analysis was performed using Cox proportional hazards analysis. To correct for potential bias in the selection of SBRT/SABR versus surgery within the multivariate analysis, we created a logistic regression model of the probability of selecting SBRT/SABR and included it as a covariate in the multivariate analysis. 12, 13 Median follow-up for the entire study population was 25.8 months (range, 3-73 months). The median follow up was 18.8 months for SBRT and 30.0 months for surgery. The median lengths of follow-up for living patients were 18.8, 35.0, and 31.0 months for the SBRT/ SABR, sublobar resection, and lobectomy patients respectively, with 66%, 90%, and 89% having been followed for 12 or more months, respectively.
RESULTS
The 2-year actuarial rates of OS, DFS, and LRC for the entire population of 317 patients were 76.8%, 79.9%, and 88.8%, respectively. The respective 5-year OS, DFS, and LRC rates were 44.6%. 53.0%, and 77.0%. A total of 74 (54.0%), 13 (27.1%), and 27 (20.4%) patients died in the SBRT, SLR, and LR groups, respectively. 15, 6, and 18 locoregional failures were seen in the SBRT, SLR, and LR Original Article groups, respectively, and distal failure occurred in 21, 4, and 14 patients in the SBRT, SBLR, and LR groups, respectively.
Matched-Pair Analysis
Factors chosen for the matched-pair analysis were drawn from univariate analysis of OS, TRC and LRC shown in Table 2 . We found that overall survival significantly correlated with histology, Charlson comorbidity index, tumor size, aspirin use, and SBRT/SABR. Univariate analysis also correlated TRC with histology. No variables significantly correlated with LRC, although the closest was tumor size: P 5 .060 (Fig. 1) .
We constructed matched-pairs to help control for selection bias when evaluating differences in OS by matching pathology, age, sex, tumor diameter, aspirin use and Charlson comorbidity index. As shown in Table 3 , Matched-pair comparisons found that OS (Fig. 2 ) remained significantly poorer in SBRT/SABR patients compared with patients undergoing either a wedge resection or a lobectomy (P 5 .003, and P < .0001)
Matched-pairs were constructed for evaluation of TRC by matching by pathology, age, size, and sex (but not Charlson comorbidity index or aspirin use, which did not appear to affect TRC or LRC to allow more patients to be included). As shown in Table 3 , matched-pair comparisons of TRC, LRC and disseminated control (DC) found no significant differences between SBRT/SABR patients compared to lobectomy or sublobar resection (Fig. 3) .
Propensity Score Table 4 shows the results of forward stepwise logistic regression analysis of the probability of choosing SBRT/ SABR (versus resection). The significant variables (age, aspirin use, Charlson comorbidity score, diabetes, NSAID use, non-small cell pathology, percentage predicted FEV1, and hypertension) were included in the propensity score (probability of choosing SBRT/SBRT) to include in proportional hazards analysis.
Multivariate Survival Analyses Table 5 shows the results of multivariate analysis of OS, performed first without a propensity score in the first 2 columns labeled P(OS) and HRR(OS) and then including the propensity score as a covariate in the last 2 columns labeled OS1 and HRR(OS1) to adjust for selection bias in treatment choice. Multivariate analysis without propensity score (PS) correction correlated better OS with surgery, lower Charlson comorbidity score, and adenocarcinoma histology. After adjustment for propensity scores, OS correlated only with Charlson comorbidity index (and the PS used for adjustment). Table 6 compares multivariate analysis of total recurrence control (TRC) without including the propensity score in the first 2 columns, P (TRC) and HRR (TRC) to the results including the propensity score as a covariate to control for selection bias. Without the propensity score, we associated improved TRC with surgery (versus SBRT/SABR) and no other variables. With the propensity score included to control for selection bias (P 5 .001), tumor grade correlated with TRC at a borderline significance of P 5 .05 but SBRT/SABR did not (P 5 .636). As shown in the last two columns, there was no correlation between type of therapy with LRC (P 5 0.424), which correlated only with increased tumor diameter (P 5 0.027) and a trend to older age (P 5 0.052) without propensity score included in the final model. With the propensity score forced into the final multivariate model, the association with tumor diameter retained significance (P 5 .026, HRR 5 1.268) and the age association was weaker (P 5 .065, HRR 5 0.973).
DISCUSSION
The majority of patients with NSCLC present with locally advanced disease. However, the widespread introduction of screening patients at high risk with low-dose helical CT may increase the number of patients found with early- stage disease. 14, 15 Hence, it is important to determine how this increasing patient population will be treated.
Currently, 2 open prospective trials randomize patients to either surgery or SBRT/SABR. A trial at the MD Anderson Cancer Center, Houston, Texas, includes patients with stage I NSCLC measuring less than 4 cm, who are treated with either SBRT/SABR or surgery (LR or pneumonectomy), with the primary outcome being OS at 3 years. The American College of Surgeons Oncology Group/Radiation Therapy Oncology Group trial Z4099/ 1021 (ClinicalTrials.gov identifier: NCT01336894) will randomly allocate patients with stage I NSCLC (smaller than 3 cm) to SLR with or without brachytherapy or to SBRT/SABR, with the primary outcome being OS at 3 years. However, the estimated completion date of the former trial is December 2017, and the latter trial just began recruiting patients in 2011. 16 Because the results of these trials, if completed, will not be available for quite some time, we feel that retrospective reviews like our may provide some clues to how these patients with early-stage lung cancer can be best managed. Unfortunately, the ROSEL trial which was conducted at Vrije Universiteit, Amsterdam, Netherlands, and randomized patients with stage IA Original Article NSCLC to surgery or SBRT was recently closed due to poor accrual. 16 Our analysis suggests that SBRT/ SABR and surgery will likely yield the same OS, TRC, and LRC in such patients. However, we strongly encourage enrollment in the ongoing randomized trials. Although, we tried to match patients treated with SBRT/SABR and surgery as best possible for prognostic variables, there are inevitably limitations to the ability of such an analysis, no mater how carefully done. Because patients receiving SBRT/SABR undergo biopsies and not a surgical resection, it is difficult to determine known prognostic factors such as tumor grade, 17, 18 lymphatic vascular invasion, 17, 19 and accurate histology. 7 It should be noted that NSCLC-NOS is a diagnosis of exclusion and is discouraged. 20 Because of the small biopsy samples associated with the SBRT/SABR patients, this patient group had a much greater percentage of NSCLC-NOS (44%) than in either surgical group (8% in both). In general, it is recommended that NSCLC-NOS be used as little as possible and only when a more specific tissue diagnosis is not available by morphology or special stains. 20 Nevertheless, our multivariate analysis for OS showed a statistically significant better outcome for adenocarcinomas which may have been due to the overuse of NSCLC-NOS in the SBRT/SABR group because of small biopsy samples. However, after adjustment for propensity score which took into to account the overuse of the term NSCLC-NOS in the patients treated with SBRT/SABR, histology was no longer significant for OS, but Charlson Comorbidity Index was significant. CCI is used to predict 10-year mortality for a patient due to 22 comorbid conditions, such as heart disease, cancer, dementia, liver disease, hemiplegia, and others.
11 CCI has been validated in patients with NSCLC. 21 In addition, because none of the SBRT/SABR patients underwent a nodal staging or dissection, the nodal status of these patients was unknown. Although the American College of Surgeons Oncology Group (ACOSOG) Z003 trial found no difference in 6-year OS, 5-year disease-free survival, local recurrence, regional recurrence, or distant recurrence rates between patients randomized to mediastinal lymph node dissection versus mediastinal lymph node sampling, 22 the prognostic detriment of nodal involvement has been well established. 23, 24 For survival, we used pathology, age, sex, tumor size, aspirin use, and Charlson comorbidity score for the MPC based on our matched-pair analysis and known prognostic factors for survival in the literature (the same factors with the exclusion of Charlson comorbidity index and aspirin use were used for the MPC for LRC and TRC). We felt that additional parameters were needed for the MPC in regards to OS because of the results of our univariate analyses and because the SBRT/SABR patients were all medically inoperable and were selected for this treatment modality because of their survival limitation. Needless to say, the OS results were still significantly worse for SBRT/ SABR versus lobectomy when the MPC for survival was originally performed without including aspirin use and Charlson comorbidity status (results not shown). However, once we adjusted the multivariate analysis for selection factors that were used for selection of SBRT/SABR (PS adjustment), there was no longer a survival advantage to surgery.
Multivariate analyses with adjustment for treatment selection did not reveal that SBRT/SABR was associated with TRC or LRC. Tumor grade and size were only factors significantly associated with TRC and LRC.
It should be noted that the database of surgicallytreated patients contains patients from 4 different academic practices as per our previous publications, 7, 8 but the SBRT/SABR database contains patients from only one institution. Because SBRT/SABR is a new technique that treats a largely poor-prognostic, medically-inoperable patient group, long patient follow-up can be difficult. We chose SBRT data from one institution because of the known relatively long follow-up at this cancer treatment facility. We acknowledge that having SBRT/SABR patients from one skilled institution may bias our results in favor of SBRT, but the techniques developed at this institution have shown the same high levels of control in a multi-institution phase 2 trial. 6 Using a propensity score to account for selection bias in the multivariate analysis provides the ability to control for the effects of greater numbers of variables and conduct the analysis in a larger number of subjects. Our multivariate analysis with propensity scores to control for selection bias cast doubt on any differences in overall survival, total recurrence control or local-regional control between SBRT/SABR and surgical resection.
CONCLUSIONS
Patients with stage I NSCLC treated with SBRT/SABR had similar TRC and LRC as patients treated with surgery but worse OS, on a matched-pair analysis. However, after adjustment for treatment selection, overall survival was no longer significantly worse for patients treated by SBRT/ SABR. Our results suggest that randomized trials are needed to eliminate selection bias in treatment assignment in order to accurately compare outcomes between these approaches. We greatly encourage the completion of the ongoing prospective, randomized trials comparing SBRT/ SABR to surgery.
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